5 completed. 5 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
| Phase 3 | 2 | Completed 2 |
Follow Artificial tears: new trials by email Literature Review of Artificial tears trials Research Report on Artificial tears
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Aqueous Humor Dynamics of NCX 470 Ophthalmic Solution NCX 470, Placebo - Open Angle Glaucoma | Phase 2 / Phase 3 | Completed | Nicox Ophthalmics, Inc. | 18 | 2023-12-12 | 2025-09-08 |
| Safety and Efficacy of Licaminlimab Ophthalmic Solution for the Treatment of Dry Eye Disease licaminlimab, vehicle of OCS-02, Artificial tears - Dry Eye Disease | Phase 2 | Completed | Oculis | 122 | 2023-11-29 | 2025-07-02 |
| Study of Efficacy and Safety of SAF312 Eye Drops in Subjects With Post-operative Corneal Induced Chronic Pain (CICP) SAF312 Placebo, SAF312 - Chronic Ocular Pain | Phase 2 | Completed | Novartis Pharmaceuticals | 153 | 2021-04-21 | 2024-10-09 |
| Dorzolamide-timolol in Combination With Anti-vascular Endothelial Growth Factor Injections for Wet Age-related Macular Degeneration Dorzolamide-timolol, Artificial tears - Neovascular Age-related Macular Degeneration, Wet Macular Degeneration | Phase 2 / Phase 3 | Completed | Wills Eye | 52 | 2017-02-08 | 2020-06-19 |
| Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis Ketotifen 4.0% Patch, Placebo, Olopatadine 0.2% - Allergic Conjunctivitis | Phase 2 | Completed | Senju USA, Inc. | 122 | 2009-02-01 | 2023-08-04 |
Conjunctivitis, Allergic (1) · Dry Eye Syndromes (1) · Eye Pain (1) · Glaucoma (1) · Glaucoma, Open-Angle (1) · Macular Degeneration (1) · Wet Macular Degeneration (1)
Nicox Ophthalmics, Inc. (1) · Novartis Pharmaceuticals (1) · Oculis (1) · Senju USA, Inc. (1) · Wills Eye (1)
United States (5) · Japan (1) · United Kingdom (1)
Gail Torkildsen, MD (1) · Jason Hsu, MD (1) · Sharon Klier, MD, MPH (1)